Question 1

Is MK-677 hard on the kidneys?

Accepted Answer

This is the most asked safety question about MK-677, and among the research behind this page there is no kidney measurement to answer it with. The two-year trial in older adults published a full list of what it tracked: body weight, fat mass, insulin sensitivity, lipid and cortisol levels, bone density, limb lean and fat mass, strength, function and quality of life. Kidney function is not on that list, and it is not reported in the summaries of the other trials either. The case report most often quoted on organ harm, which describes one patient, lists oedema, increased appetite and muscle pain as the familiar complaints, and oedema is fluid swelling in the tissues. Swelling is sometimes read online as a kidney warning. That report does not connect it to the kidneys, and it would be guesswork for this page to do so. An unmeasured organ is a gap rather than a clean result. The honest position is that kidney safety was simply not tested in the work covered here, which does not tell a reader that the kidneys are spared or that they are harmed.

Question 2

Does MK-677 hurt your liver?

Accepted Answer

It has been linked to liver injury in single case reports, and the controlled trials covered here do not report liver tests in their summaries. The cleanest case, published in 2025, is an otherwise healthy man in his early 30s who developed transaminitis after taking MK-677 for 2 months before he presented. Transaminitis means the liver enzymes ALT and AST were raised in the blood, a sign that liver cells were under strain. His liver function tests eventually returned to normal after he stopped, and the authors note that reports of hepatotoxicity, meaning drug-induced liver damage, are scarce. A 2022 case of combined use recorded aspartate aminotransferase up 95.8% and alanine aminotransferase up 205.0% on cycle, but that man was also taking LGD-4033, a selective androgen receptor modulator. With two compounds on board, the rise cannot be assigned to either one. Running the other way, a registered phase 2 trial tested ibutamoren in nonalcoholic fatty liver disease and is listed as completed, with no results among these sources. Two cases, one of them confounded, both settling after the compound was stopped: that is a signal worth knowing about, but it is not a rate, and it does not establish how often the liver reacts.

Question 3

What side effects did the controlled trials record?

Accepted Answer

The trials describe their adverse findings briefly, and the wording matters more than it first appears. The two-year trial reports that MK-677 lifted growth hormone and IGF-1 to young-adult levels without serious adverse effects, in 65 people aged 60 to 81. A crossover trial in eight calorie-restricted volunteers reports the compound was without clinically significant adverse experiences over its seven days of dosing. The largest trial, in 292 older women, noted side effects driven by growth hormone in the groups taking MK-677, while adverse events leading to withdrawal were relatively infrequent. A 2026 scoping review of six popular compounds names cardiovascular complications and metabolic dysfunction such as insulin resistance among the documented risks. No serious adverse effects in 65 people over two years is a real finding. It is also a statement about a trial of that size, which cannot detect an event that strikes one person in several hundred.

Question 4

Does MK-677 raise blood sugar enough to matter?

Accepted Answer

It changes glucose handling in most trial populations, and the way it shows up depends on which test is used. In 24 obese men on 25 mg a day for eight weeks, fasting glucose and insulin stayed unchanged, yet an oral glucose tolerance test showed impaired glucose homeostasis at both two and eight weeks. A glucose tolerance test gives a sugar drink and tracks how fast blood sugar comes back down, so it can catch a problem that a single fasting reading misses. In older adults the fasting value itself moved, with fasting glucose rising from 5.4 to 6.8 mmol/L over four weeks of MK-677. The 2018 review of the class traces the rise to decreases in insulin sensitivity, meaning the body needs more insulin to move the same sugar. Every one of those trials enrolled people who were healthy or obese without diabetes. How the effect plays out in someone whose glucose control is already strained was not tested, and a normal fasting result does not show that the effect is absent.

Question 5

Is MK-677 a risk for the heart?

Accepted Answer

One controlled trial raised a heart failure signal, and the rest of the heart evidence is laboratory work. The 2011 hip fracture trial randomised 123 older patients, 62 to MK-0677 at 25 mg a day and 61 to placebo, and was ended early because of a safety signal of congestive heart failure in a limited number of patients. Congestive heart failure is the heart failing to pump enough to keep fluid from backing up into the lungs and legs. In isolated rat heart muscle, MK-677 at 1 microM reduced contractility, the force of each beat, without changing how force responded to beat rate. A strip of rat heart in a bath and a frail patient after surgery are very different settings, and the two findings cannot be added together. They point the same way only loosely. What the record supports is that the one population followed while ill produced a heart signal. Whether it reaches younger or healthier users has not been asked in any trial behind this page.

Question 6

Does MK-677 raise cholesterol?

Accepted Answer

The only lipid figures among these sources come from one man taking it with a second compound. In that 2022 case, a 25-year-old took LGD-4033 at 10 mg and MK-677 at 15 mg daily for five weeks. On cycle his cholesterol rose 14.8%, triglycerides 39.2% and LDL cholesterol 40.0%, while HDL cholesterol fell 36.4%. LDL is the cholesterol linked to artery plaque and HDL the kind that helps clear it, so both moved in the unwelcome direction. The two-year trial listed lipid levels among its end points, but its summary does not report what happened to them. So the lipid question is open. One combined case is suggestive at most, and the controlled data that would settle it are not in the published summaries covered here.

Question 7

What are the potential side effects of stopping MK-677?

Accepted Answer

No withdrawal syndrome is described among the research behind this page, and the off-cycle data come from one case. In the 2022 case of combined use, most measures returned to where they started after stopping, apart from total fat mass, appendicular fat mass, bone area, total cholesterol and LDL cholesterol. Appendicular means the arms and legs, so fat gained there was still present after the cycle ended. Follicle-stimulating hormone, which drives sperm production, sat below clinical reference values both on cycle at 1.2 IU/L and after it at 1.3 IU/L. In the liver case, by contrast, the enzymes settled once the compound was stopped. What persisted in the combined case cannot be split between LGD-4033 and MK-677. The record shows some changes reversing and some not, which is different from showing what stopping MK-677 alone does.

Question 8

How long has daily MK-677 been followed in people?

Accepted Answer

Every trial used once-daily dosing by mouth, and the longest ran two years. The short end is a week: children with growth hormone deficiency took ibutamoren for 7 to 8 days, and calorie-restricted volunteers for seven. In the middle sit the 1996 trial in older adults, run as study periods of 14 and 28 days, and the eight-week trial in obese men. At the long end, the bone trial gave treatment for 12 months and followed density for 18, and the two-year trial was a double-blind, modified-crossover design. The 2018 review of the class judges that few long-term, rigorously controlled studies exist and asks for long-term safety work that includes cancer incidence and mortality. Two years in 65 older adults is the ceiling of the controlled record. It does not tell a 25-year-old what a decade would do.

Question 9

Who was left out of the MK-677 trials?

Accepted Answer

The trials were built around ageing, illness and childhood growth, and the people in the case reports are mostly the ones missing from them. The adult trials enrolled people aged 64 to 81, women aged 64 to 85 with low bone density, obese men aged 18 to 50, and elderly patients recovering from hip fracture. The youngest healthy adults were eight volunteers aged 24 to 39, studied for a week under calorie restriction. The harm reports describe a different group: a 25-year-old, a man in his early 30s, and a 54-year-old who had been using MK-677 and RAD-140 for bodybuilding purposes. Young men who train, people with diagnosed diabetes and anyone combining compounds do not appear among the trial populations described here. That is precisely the group the case reports come from, and it is the group the trials cannot speak for.

Question 10

What does MK-677 interact with?

Accepted Answer

Three kinds of interaction appear in the record, and only one was tested in a controlled trial. Alongside alendronate, a bone drug, MK-677 attenuated the indirect suppressive effect of alendronate on bone formation in the 2001 trial in older women. A 1998 review of the class reports that its effect on growth hormone release is synergistic with that of GHRH, the brain's own growth-hormone-releasing signal, meaning the two together produce more than either alone. The third kind is combination with selective androgen receptor modulators, which appears only in case reports. LGD-4033 accompanied the lipid and testosterone changes, and RAD-140 accompanied the spleen rupture, so neither case can separate the two compounds. Combination can also happen without the buyer knowing, since a 2021 analysis found MK-677 and YK-11, not disclosed on the label, inside some supplements. A synergy measured in hormone tests does not tell a reader about harm by itself. It does mean that stacking MK-677 with other growth hormone releasers changes the exposure in ways no trial behind this page measured.

Question 11

Could MK-677 affect the spleen or blood vessels?

Accepted Answer

One case raises the question, and its own authors decline to answer it. A 2026 report describes a 54-year-old man who came to an emergency department with acute pain in the upper left abdomen and vomiting, and whose scan showed a large perisplenic hematoma consistent with splenic rupture. He needed embolization and then an emergency laparotomy with total splenectomy, meaning surgical removal of the spleen. The tissue showed large areas of splenic infarction, with features raising the possibility of an underlying vascular malformation, an abnormal tangle of blood vessels. The authors state that RAD-140 and MK-677 have not been previously linked to splenic pathology, and call their role potential and speculative. One case with a second compound and a possible pre-existing malformation cannot establish a link. It is recorded here because it is in the literature, not because it shows MK-677 causes rupture.

Question 12

Does MK-677 raise prolactin or cortisol?

Accepted Answer

Both rise at first, and in most trials they stay within or return to the normal range. In older adults, prolactin rose 23% on MK-677 but remained within the normal range, while cortisol did not change. Prolactin is a pituitary hormone best known for its part in milk production, and it is one of the hormones this class of compound can pull upward alongside growth hormone. In the trial in obese men, growth hormone and prolactin were significantly increased after the first dose, and the effects on cortisol were transient. In the calorie-restriction trial, neither cortisol nor prolactin responded more after seven days of MK-677 than after seven days of placebo. These are measurements in groups over weeks. They show the pituitary responding beyond growth hormone alone, and they cannot rule out a larger response in an individual or over a longer course.

Question 13

How soon do side effects show up?

Accepted Answer

Faster than most people assume, and on different clocks for different effects. Glucose handling was already impaired at the two-week glucose tolerance test in obese men, the earliest point that trial checked. Fasting glucose in older adults had risen significantly by four weeks. The liver case presented after two months of use, and the combined case recorded its lipid, liver and hormone shifts within a five-week cycle. The heart failure signal arose inside a trial planned to run 24 weeks, which reported its outcomes at that point. The early effects are the metabolic ones, and they appear within weeks. How quickly rarer harms emerge cannot be read from these sources, because a few cases and one stopped trial do not trace a timeline.

MK-677 side effects and safety data